Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
7 min read
Analysis on the Clinical Research Progress of ERK Inhibitor
2 November 2023
ERK, also known as Extracellular Signal-Regulated Kinase, is a crucial protein kinase that plays a significant role in various cellular processes within the human body.
Latest Hotspot
3 min read
The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL
2 November 2023
Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.
Drug Insights
4 min read
Pharmaceutical Insights: Cocaine Hydrochloride's R&D Progress
2 November 2023
This article summarized the latest R&D progress of Cocaine Hydrochloride, the mechanism of action for Cocaine Hydrochloride, and the drug target R&D trends for Cocaine Hydrochloride.
Latest Hotspot
3 min read
The novel Aβ-targeting drug Donanemab by Eli Lilly is applying for market authorization in China to treat Alzheimer's disease
2 November 2023
Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.
Valuable Targets
6 min read
Advances in Clinical Research on D2 Receptor Antagonist
2 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Latest Hotspot
3 min read
The positive data from Apellis' Phase 3 study on pegcetacoplan was published in The Lancet, targeting the main cause of blindness in the elderly
1 November 2023
Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .
Drug Insights
3 min read
Exploring Dactinomycin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
1 November 2023
This article summarized the latest R&D progress of Dactinomycin, the Mechanism of Action for Dactinomycin, and the drug target R&D trends for Dactinomycin.
Latest Hotspot
4 min read
The latest phase II clinical research by Innovent Biologics on Mazdutide, a GLP-1R/GCGR dual agonist, has been released, showing significant weight loss effects
1 November 2023
Innovent Biologics recently announced the completion of the 48-week treatment phase after reaching the primary endpoint of the phase II clinical trial in obese Chinese subjects with 9mg of the GLP-1R/GCGR dual agonist, Mazdutide.
Advanced Tech.
6 min read
Molecular Glue: It bonds proteins and challenges the undruggable
1 November 2023
Molecular glue can enhance and stabilize protein interactions; it can also repair protein interactions that have been weakened due to mutations.
Latest Hotspot
3 min read
The Eli Lilly IL-13 inhibitor, lebrikizumab, demonstrates long-term efficacy for the treatment of moderate-to-severe atopic dermatitis
1 November 2023
Recently, Eli Lilly announced the long-term therapeutic effects of its investigational IL-13 inhibitor, lebrikizumab, in patients with moderate to severe atopic dermatitis.
Drug Insights
4 min read
Deep Scientific Insights on Dopamine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
1 November 2023
This article summarized the latest R&D progress of Dopamine hydrochloride, the mechanism of action for Dopamine hydrochloride, and the drug target R&D trends for Dopamine hydrochloride.
Latest Hotspot
3 min read
Abbisko Therapeutics' EGFR exon20ins inhibitor, ABSK112, has been approved for clinical use in China for the treatment of non-small cell lung cancer
1 November 2023
Recently, Abbisko Therapeutics announced that its independently developed next-generation EGFR Exon20ins inhibitor ABSK112 has received approval from the NMPA of China for clinical trial applications.